PMID- 7777536
OWN - NLM
STAT- MEDLINE
DCOM- 19950712
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 92
IP  - 12
DP  - 1995 Jun 6
TI  - Growth factors can enhance lymphocyte survival without committing the cell to 
      undergo cell division.
PG  - 5491-5
AB  - Growth factors have been defined by their ability to promote the proliferative 
      expansion of receptor-bearing cells. For example, antigen-activated T cells 
      expressing the alpha beta gamma form of the interleukin 2 (IL-2) receptor will 
      proliferate in response to IL-2. In contrast, resting T cells, which express the 
      IL-2 receptor beta and gamma chains, do not proliferate in response to IL-2. We 
      demonstrate that the survival of resting T cells following gamma irradiation is 
      greatly enhanced by pretreatment with IL-2. The radioprotective effect of IL-2 is 
      dose dependent, does not result from the induction of cell proliferation, and 
      does not require expression of the IL-2 receptor alpha chain. Thus, the beta 
      gamma IL-2 receptor expressed on resting T cells can transduce signals that 
      promote cell survival without committing the T cell to undergo cell division. 
      IL-4 and IL-7, but not IL-1, IL-3, or IL-6, were also found to enhance the 
      survival of quiescent T cells following gamma irradiation. Thus, certain growth 
      factor-receptor interactions can serve to maintain cell viability in a manner 
      that is independent of their ability to initiate or maintain cell proliferation. 
      These data may have important implications for the use of growth factors in 
      patients being treated with radiation and/or chemotherapy.
FAU - Boise, L H
AU  - Boise LH
AD  - Gwen Knapp Center, Howard Hughes Medical Institute, University of Chicago, IL 
      60637, USA.
FAU - Minn, A J
AU  - Minn AJ
FAU - June, C H
AU  - June CH
FAU - Lindsten, T
AU  - Lindsten T
FAU - Thompson, C B
AU  - Thompson CB
LA  - eng
GR  - P01 A135294/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (BCL2L1 protein, human)
RN  - 0 (Interleukins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (bcl-X Protein)
SB  - IM
MH  - Apoptosis
MH  - Cell Division
MH  - Cell Survival
MH  - Cells, Cultured
MH  - Gamma Rays
MH  - Humans
MH  - Interleukins/*pharmacology
MH  - Lymphocyte Activation
MH  - Proto-Oncogene Proteins/genetics
MH  - Proto-Oncogene Proteins c-bcl-2
MH  - T-Lymphocytes/*cytology/metabolism/radiation effects
MH  - bcl-X Protein
PMC - PMC41721
EDAT- 1995/06/06 00:00
MHDA- 1995/06/06 00:01
PMCR- 1995/12/06
CRDT- 1995/06/06 00:00
PHST- 1995/06/06 00:00 [pubmed]
PHST- 1995/06/06 00:01 [medline]
PHST- 1995/06/06 00:00 [entrez]
PHST- 1995/12/06 00:00 [pmc-release]
AID - 10.1073/pnas.92.12.5491 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5491-5. doi: 10.1073/pnas.92.12.5491.